You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

HER2 Amplification

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Recurrent/Advanced Gastric Cancer Trial in Seoul (Chemotherapy)

Not yet recruiting
  • Recurrent/Advanced Gastric Cancer
  • Seoul, Korea, Republic of
    Yonsei University Health System, Severance Hospital
Aug 22, 2022

HER2 Mutant NSCLC, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation Trial (ELVN-002, Fam-Trastuzumab Deruxtecan-Nxki,

Not yet recruiting
  • HER2 Mutant Non-small Cell Lung Cancer
  • +3 more
  • (no location specified)
Dec 6, 2022

Advanced Malignant Solid Tumor, EGFR Gene Amplification, EGFR Gene Mutation Trial in Houston (Everolimus, Neratinib,

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +9 more
  • Houston, Texas
    M D Anderson Cancer Center
Oct 25, 2022

Malignant Solid Tumor Trial in Philadelphia (Biopsy, Biospecimen Collection, Echocardiography)

Active, not recruiting
  • Malignant Solid Neoplasm
  • Biopsy
  • +5 more
  • Philadelphia, Pennsylvania
    ECOG-ACRIN Cancer Research Group
Nov 15, 2023

HER2 Mutation-Related Tumors, HER2 Amplification Trial (ARX788)

Not yet recruiting
  • HER2 Mutation-Related Tumors
  • HER2 Amplification
  • (no location specified)
Aug 23, 2021

Chemotherapy Combined With Immunotherapy in HER 2 Insertion or

Recruiting
  • Non Small Cell Lung Cancer
    • Changsha, Hunan, China
      Yongchang Zhang
    Mar 1, 2022

    HER2-positive Breast Cancer, HER-2 Protein Overexpression, HER-2 Gene Amplification Trial in San Antonio, Fairfax (ORM-5029)

    Not yet recruiting
    • HER2-positive Breast Cancer
    • +3 more
    • San Antonio, Texas
    • +1 more
    Aug 22, 2022

    Solid Tumor, Haematological Malignancy, Colorectal Tumors Trial in United Kingdom (Trastuzumab, Pertuzumab)

    Recruiting
    • Solid Tumor
    • +10 more
    • Belfast, United Kingdom
    • +25 more
    Mar 28, 2023

    Esophageal Squamous Cell Carcinoma, HER-2 Protein Overexpression, HER-2 Gene Amplification Trial in Copenhagen, Odense

    Recruiting
    • Esophageal Squamous Cell Carcinoma
    • +2 more
    • Copenhagen, Region H, Denmark
    • +1 more
    Aug 10, 2022

    HER-2 Gene Amplification, HER2-positive Gastric Cancer, HER2-positive Breast Cancer Trial in United States (chimeric antigen

    Recruiting
    • HER-2 Gene Amplification
    • +4 more
    • chimeric antigen receptor (CAR) T cell therapy
    • Duarte, California
    • +6 more
    Aug 10, 2022

    Safety Trial in GuangZhou (Almonertinib combine with Pyrrolitinib)

    Recruiting
    • Safety
    • Almonertinib combine with Pyrrolitinib
    • GuangZhou, Guang Dong, China
      Sun Yat-sen University Cancer Center
    Mar 4, 2021

    Carcinoma, Transitional Cell, HER-2 Gene Amplification Trial in Beijing (Trastuzumab)

    Recruiting
    • Carcinoma, Transitional Cell
    • HER-2 Gene Amplification
    • Beijing, China
      National Cancer Center/Cancer Hospital, Chinese Academy of Medic
    Mar 31, 2022

    HER2-positive, Adenocarcinoma, Bile Duct Cancer Trial in United States (CT-0508)

    Recruiting
    • HER2-positive
    • +30 more
    • CT-0508
    • Duarte, California
    • +4 more
    Feb 1, 2022

    Breast Cancer Trial in United States (Margetuximab)

    Completed
    Has Results
    • Breast Cancer
    • Margetuximab
    • San Francisco, California
    • +5 more
    Feb 4, 2022

    ER+ Breast Cancer, CCNE1 Amplification, HER2-negative Breast Cancer Trial in United States (BLU-222, Carboplatin, Ribociclib)

    Recruiting
    • ER+ Breast Cancer
    • +8 more
    • Sarasota, Florida
    • +3 more
    Jun 8, 2022

    Cholangiocarcinoma, Biliary Tract Cancer, HER-2 Protein Overexpression Trial in Seoul (Trastuzumab)

    Completed
    • Cholangiocarcinoma
    • +3 more
    • Seoul, Korea, Republic of
      Asan Medical Center
    Jan 4, 2021

    Advanced NSCLC Trial in Shanghai (SHR-A1811)

    Recruiting
    • Advanced Non-small Cell Lung Cancer
    • Shanghai, Shanghai, China
      Shanghai Chest Hospital
    Jun 1, 2021

    HER2-Positive Cancer Trial in Wuhan

    Active, not recruiting
    • HER2-Positive Cancer
      • Wuhan, Hubei, China
        TongjiHospital
      Sep 7, 2022

      Ewing Sarcoma, Myxoid/Round Cell Liposarcoma, Synovial Sarcoma Trial in United States (PRT2527)

      Recruiting
      • Ewing Sarcoma
      • +7 more
      • Denver, Colorado
      • +5 more
      Jun 9, 2022

      HER2 Mutation-Related Tumors, HER2 Amplified Solid Tumors Trial in Miami Beach, Kansas City (ARX788)

      Withdrawn
      • HER2 Mutation-Related Tumors
      • HER2 Amplified Solid Tumors
      • Miami Beach, Florida
      • +1 more
      Apr 22, 2022

      HER2 and LA/mUC: A Multi-country Chart Review Cohort Study

      Not yet recruiting
      • Urothelial Carcinoma
        • (no location specified)
        Jun 5, 2023

        HER2, Colorectal Cancer Trial (Disitamab Vedotin Combined With Fruquintinib)

        Not yet recruiting
        • HER2
        • Colorectal Cancer
        • Disitamab Vedotin Combined With Fruquintinib
        • (no location specified)
        Dec 21, 2022

        Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Metastasis Trial in United States (Oxaliplatin, Leucovorin, 5 fluorouracil)

        Active, not recruiting
        • Gastric Adenocarcinoma
        • +3 more
        • Duarte, California
        • +6 more
        May 10, 2021

        Metastatic Breast Cancer Trial in Rome (HER2-D is the use of a non-invasive liquid biopsy method to non-invasively and

        Recruiting
        • Metastatic Breast Cancer
        • HER2-D is the use of a non-invasive liquid biopsy method to non-invasively and objectively assess HER2 status at recruitment
        • Rome, Italy
          Fondazione Policlinico A. Gemelli - IRCCS
        Jun 22, 2023

        Metastatic Gastric Cancer, PD-L1 Gene Amplification, FGFR2 Amplification Trial in New York (Nivolumab, Capecitabine,

        Recruiting
        • Metastatic Gastric Cancer
        • +2 more
        • New York, New York
          Bureau for Cancer Research
        May 10, 2023